[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Piechocki MP, Yoo GH, Dibbley SK, Amjad EH, Lonardo F: Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. Int J Cancer; 2006 Jul 15;119(2):441-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu.
  • Understanding the role of signal transduction in regulating pathways responsible for cell growth, survival and apoptosis is critical for cancer therapy.
  • We developed and characterized a HER2/neu and Fas overexpressing cell line (BNT.888 ACA2) from a salivary gland adenocarcinoma that arose in a HER2/neu transgenic mouse.
  • Iressa treatment diminished phosphorylation of the HER2/neu and EGFR.
  • These data showing that Iressa induces cytostasis and primes the extrinsic (Fas) and intrinsic (mitochondrial and endoplasmic reticulum) apoptotic pathways should lead to the development of novel therapeutic targets and strategies.
  • [MeSH-major] Antigens, CD95 / metabolism. Antineoplastic Agents / pharmacology. Carcinoma, Acinar Cell / drug therapy. Neoplasm Proteins / drug effects. Quinazolines / pharmacology. Receptor, ErbB-2 / metabolism. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Caspases / drug effects. Caspases / metabolism. Cell Cycle / drug effects. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Immunohistochemistry. Male. Mice. Mice, Inbred BALB C. Mice, Transgenic. Mitogen-Activated Protein Kinase Kinases / drug effects. Mitogen-Activated Protein Kinase Kinases / metabolism. Phosphorylation / drug effects. Poly(ADP-ribose) Polymerases / drug effects. Poly(ADP-ribose) Polymerases / metabolism. Signal Transduction / drug effects. Up-Regulation


2. Piechocki MP, Lonardo F, Ensley JF, Nguyen T, Kim H, Yoo GH: Anticancer activity of docetaxel in murine salivary gland carcinoma. Clin Cancer Res; 2002 Mar;8(3):870-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticancer activity of docetaxel in murine salivary gland carcinoma.
  • PURPOSE: The purpose of this study was to evaluate the biological mechanisms of docetaxel (TXT) on salivary gland carcinoma.
  • EXPERIMENTAL DESIGN: The effects of TXT on a spontaneous murine salivary carcinoma were determined.
  • RESULTS: We characterized a spontaneous mouse salivary gland carcinoma (SGC1).
  • SGC1 is a poorly differentiated carcinoma that originated from the parotid gland of a BALB/c mouse.
  • CONCLUSIONS: We have identified several novel targets of TXT that contribute to its antitumor activity in poorly differentiated salivary gland carcinoma.
  • These results suggest that TXT may be appropriate for additional in vivo studies and clinical trials in patients with salivary cancers.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / analogs & derivatives. Paclitaxel / therapeutic use. Salivary Gland Neoplasms / drug therapy. Taxoids
  • [MeSH-minor] Animals. Antigens, CD95 / metabolism. Apoptosis / drug effects. Blotting, Western. Cell Communication / drug effects. Cell Cycle / drug effects. Cell Division / drug effects. Connexin 43 / metabolism. Female. Flow Cytometry. Fluorescent Antibody Technique. Gap Junctions / drug effects. Immunoenzyme Techniques. Keratins / metabolism. Mice. Mice, Inbred BALB C. Mice, SCID. Precipitin Tests. Proliferating Cell Nuclear Antigen / metabolism. S100 Proteins / metabolism. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11895921.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antineoplastic Agents, Phytogenic; 0 / Connexin 43; 0 / Proliferating Cell Nuclear Antigen; 0 / S100 Proteins; 0 / S100A1 protein; 0 / Taxoids; 15H5577CQD / docetaxel; 68238-35-7 / Keratins; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


3. Uematsu T, Hasegawa T, Hiraoka BY, Komatsu F, Matsuura T, Yamada AS, Yamaoka M: Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas. Int J Cancer; 2001 Apr 15;92(2):187-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas.
  • In combined chemotherapy for head-and-neck cancer (HNC), salivary gland-cell adenocarcinoma (SGA) shows insufficient clinical outcome, and it has been suggested that the sensitivity and/or the mechanism of resistance to anti-cancer drugs are different between SGA and oral squamous-cell carcinoma (SCC).
  • In immunohistochemical analysis, P-gp expression was found in the ductal cells of salivary glands but not in oral mucosal epithelium.
  • In cancer tissues, a few SCC cells in 12 of 37 and most cells in all SGAs expressed P-gp.
  • However, P-gp expression was developed in both HSY and Hepd cell lines after vincristine (VCR) treatment.
  • RT-PCR showed that the mean ratios of mdr1 mRNA expression levels in HSY clones were 3.7-fold higher than those in Hepd clones after VCR treatment, while each cell line exhibited both induction and activated production of P-gp.
  • These results suggest that P-gp-related MDR in SGA is an inherent phenotype caused by both high levels of P-gp induction and activated P-gp production during VCR treatment, while that in SCC is an acquired phenotype chiefly caused by induction of P-gp.
  • [MeSH-major] Adenocarcinoma / genetics. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Squamous Cell / genetics. Drug Resistance, Neoplasm. Genes, MDR. Mouth Neoplasms / genetics. Salivary Gland Neoplasms / genetics. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Aged. Animals. Cell Division / drug effects. Cell Survival / drug effects. Drug Resistance, Multiple. Female. Gene Expression Regulation, Neoplastic. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / metabolism. Humans. Male. Mice. Mice, Nude. Middle Aged. P-Glycoprotein / biosynthesis. RNA, Messenger / biosynthesis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11291044.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / P-Glycoprotein; 0 / RNA, Messenger; 5J49Q6B70F / Vincristine
  •  go-up   go-down


Advertisement
4. Dahse R, Kosmehl H: Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. Br J Cancer; 2008 Jul 8;99(1):90-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.
  • Activating mutations within the epidermal growth factor receptor (EGFR) identify lung adenocarcinoma patients with improved clinical responses to tyrosine kinase inhibitors gefitinib and erlotinib.
  • By screening salivary gland carcinoma, two drug-sensitizing EGFR exon 19 delE746-A750 mutations were identified in an adenocystic and in a mucoepidermoid carcinoma of the parotid gland.
  • [MeSH-major] Drug Resistance / genetics. Parotid Neoplasms / drug therapy. Parotid Neoplasms / genetics. Protein Kinase Inhibitors / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Aged. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Mucoepidermoid / drug therapy. Carcinoma, Mucoepidermoid / genetics. DNA, Neoplasm / genetics. Erlotinib Hydrochloride. Exons. Female. Humans. Male. Middle Aged. Mutation. Quinazolines / therapeutic use

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):396-403 [16049312.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] Pathol Int. 2007 May;57(5):233-44 [17493170.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):729-34 [17350323.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • (PMID = 18542074.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ PMC2453031
  •  go-up   go-down


5. Jones SJ, Laskin J, Li YY, Griffith OL, An J, Bilenky M, Butterfield YS, Cezard T, Chuah E, Corbett R, Fejes AP, Griffith M, Yee J, Martin M, Mayo M, Melnyk N, Morin RD, Pugh TJ, Severson T, Shah SP, Sutcliffe M, Tam A, Terry J, Thiessen N, Thomson T, Varhol R, Zeng T, Zhao Y, Moore RA, Huntsman DG, Birol I, Hirst M, Holt RA, Marra MA: Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol; 2010;11(8):R82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.
  • BACKGROUND: Adenocarcinomas of the tongue are rare and represent the minority (20 to 25%) of salivary gland tumors affecting the tongue.
  • We investigated the utility of massively parallel sequencing to characterize an adenocarcinoma of the tongue, before and after treatment.
  • RESULTS: In the pre-treatment tumor we identified 7,629 genes within regions of copy number gain.
  • The observed mutations and amplifications were consistent with therapeutic resistance arising through activation of the MAPK and AKT pathways.
  • CONCLUSIONS: We conclude that complete genomic characterization of a rare tumor has the potential to aid in clinical decision making and identifying therapeutic approaches where no established treatment protocols exist.
  • These results also provide direct in vivo genomic evidence for mutational evolution within a tumor under drug selection and potential mechanisms of drug resistance accrual.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Gene Expression Regulation, Neoplastic / drug effects. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-ret / genetics
  • [MeSH-minor] Benzenesulfonates / pharmacology. Benzenesulfonates / therapeutic use. Gene Dosage / drug effects. Genes, Neoplasm / drug effects. High-Throughput Nucleotide Sequencing. Humans. Indoles / pharmacology. Indoles / therapeutic use. Lung Neoplasms / secondary. Mitogen-Activated Protein Kinases / metabolism. Mutation. Neoplasm Proteins / genetics. Niacinamide / analogs & derivatives. Phenylurea Compounds. Proto-Oncogene Proteins c-akt / metabolism. Pyridines / pharmacology. Pyridines / therapeutic use. Pyrroles / pharmacology. Pyrroles / therapeutic use. Selection, Genetic. Tongue Neoplasms / drug therapy. Tongue Neoplasms / genetics. Tongue Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):308-11 [11125122.001]
  • [Cites] Neoplasia. 1999 Jun;1(2):101-6 [10933042.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4340-6 [14555504.001]
  • [Cites] Auris Nasus Larynx. 2004 Mar;31(1):85-8 [15041060.001]
  • [Cites] Laryngoscope. 1987 May;97(5):533-6 [3573898.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):256-61 [7522539.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] J Laryngol Otol. 1996 Jul;110(7):700-3 [8759555.001]
  • [Cites] Otolaryngol Head Neck Surg. 1997 Nov;117(5):448-52 [9374165.001]
  • [Cites] J Cell Biol. 1998 Nov 30;143(5):1375-83 [9832564.001]
  • [Cites] Diagn Mol Pathol. 2005 Jun;14(2):77-82 [15905690.001]
  • [Cites] Lab Invest. 2005 Sep;85(9):1076-85 [16025147.001]
  • [Cites] Nat Rev Drug Discov. 2005 Dec;4(12):988-1004 [16341064.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-72 [16381955.001]
  • [Cites] Bioinformatics. 2006 Jul 15;22(14):e431-9 [16873504.001]
  • [Cites] BMC Genomics. 2006;7:246 [17010196.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1562-7 [17088901.001]
  • [Cites] Nat Rev Cancer. 2007 Jan;7(1):35-45 [17167516.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):240-6 [17255769.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] Lung Cancer. 2007 Apr;56(1):25-33 [17175059.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5779-88 [17575145.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):94-104 [17490733.001]
  • [Cites] PLoS Biol. 2007 Sep 4;5(10):e254 [17803354.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Mar 7;367(2):291-8 [18155156.001]
  • [Cites] Nature. 2008 Apr 17;452(7189):872-6 [18421352.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):722-9 [18438408.001]
  • [Cites] Nat Methods. 2008 Jul;5(7):621-8 [18516045.001]
  • [Cites] Biotechniques. 2008 Jul;45(1):81-94 [18611170.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Genome Res. 2008 Nov;18(11):1851-8 [18714091.001]
  • [Cites] Nature. 2008 Nov 6;456(7218):53-9 [18987734.001]
  • [Cites] Nature. 2008 Nov 6;456(7218):66-72 [18987736.001]
  • [Cites] BMC Genomics. 2008;9:488 [18925949.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D690-7 [19033362.001]
  • [Cites] PLoS One. 2009;4(1):e4108 [19119315.001]
  • [Cites] Biochem Pharmacol. 2009 Feb 1;77(3):297-309 [19028457.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2719-29 [19516027.001]
  • [Cites] Genome Res. 2009 Sep;19(9):1639-45 [19541911.001]
  • [Cites] Nature. 2009 Oct 8;461(7265):809-13 [19812674.001]
  • [Cites] Cancer Res. 2010 Feb 1;70(3):1063-71 [20103651.001]
  • [Cites] Nat Genet. 2010 Feb;42(2):181-5 [20081860.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5403-7 [10554005.001]
  • [Cites] Nucleic Acids Res. 2000 Jan 1;28(1):27-30 [10592173.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):222-31 [11902577.001]
  • (PMID = 20696054.001).
  • [ISSN] 1474-760X
  • [Journal-full-title] Genome biology
  • [ISO-abbreviation] Genome Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Indoles; 0 / Neoplasm Proteins; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2945784
  •  go-up   go-down


6. Zhao J, Wang MZ, Li LY, Zhang L, Zhong W: [Clinical features of pulmonary malignancies in patients younger than 30 years of age]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Apr;32(2):174-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Out of these 58 patients, adenocarcinoma was most common (n=23, 39.66%).
  • The mean time from the onset of disease to confirmed diagnosis was (5.98+/-8.95) months.
  • The proportion of tumors in limited stage was 72.73% in 11 patients with small cell lung cancer, and most patients (54.55) were not sensitive to conventional chemotherapy.
  • In 6 patients with carcinoid, 4 patients were central and the other 2 patients were peripheral, and all of them presented as Cushing syndrome; CgA, AE1/AE3, Syn, and NSE were positive in immunohistochemical staining; and surgical operation was the main treatment for them.
  • In 6 patients with carcinomas of salivary gland type, all cases were central; no lymph nodes metastasis was found in the postoperative specimen; and surgical operation was also the main treatment for these patients.
  • Multiple nodules in bilateral lungs were presented in 2 patients with anaplastic large cell lymphomas, in which CD30 was positive in tumor cells; chemotherapy was the main therapy for these two patients.
  • The treatment strategy should be based on the specific conditions of each patient.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450548.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Park JH, Moon YH, Kim DJ, Kim SA, Lee JB, Ahn SG, Yoon JH: Photodynamic therapy with hexenyl ester of 5-aminolevulinic acid induces necrotic cell death in salivary gland adenocarcinoma cells. Oncol Rep; 2010 Jul;24(1):177-81
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with hexenyl ester of 5-aminolevulinic acid induces necrotic cell death in salivary gland adenocarcinoma cells.
  • Photodynamic therapy has been developed as an alternative therapy of cancer.
  • The aim of this study was to examine whether PDT with hexenyl ester of 5-aminolaevulinic acid (ALA-hx) inhibits the proliferation of the salivary gland adenocarcinoma SGT cells.
  • Treatment of ALA-hx induced CPO mRNA expression and ROS was produced by ALA-hx PDT in SGT cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Photochemotherapy. Salivary Gland Neoplasms / drug therapy. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / pharmacology. Aminolevulinic Acid / therapeutic use. Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cell Death / drug effects. Cell Death / genetics. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / genetics. Chick Embryo. Coproporphyrinogen Oxidase / genetics. Coproporphyrinogen Oxidase / metabolism. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Humans. Necrosis / chemically induced. Necrosis / genetics. Necrosis / metabolism. Neoplasm Invasiveness. Reactive Oxygen Species / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514459.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Reactive Oxygen Species; 88755TAZ87 / Aminolevulinic Acid; EC 1.3.3.3 / Coproporphyrinogen Oxidase; G7H20TKI67 / 5-aminolevulinic acid hexyl ester
  •  go-up   go-down


8. Naramoto H, Uematsu T, Uchihashi T, Doto R, Matsuura T, Usui Y, Uematsu S, Li X, Takahashi M, Yamaoka M, Furusawa K: Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines. Int J Oncol; 2007 Feb;30(2):393-401
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines.
  • For in vitro and in vivo chemotherapeutic studies, we used the following head and neck cancer cell lines: a mouse oral squamous cell carcinoma (SCC) cell line, Sq-1979; a human SCC cell line, SCCHA; a mouse salivary gland adenocarcinoma (SGA) cell line, NR-PG; and a human SGA cell line, HSY.
  • We used a vinca alkaloid anticancer drug, vincristine (VCR), as a chemotherapeutic anticancer drug.
  • To determine the cause of multidrug resistance, Western blot analysis, reverse transcription-polymerase chain reaction (RT-PCR), immunohistochemistry of xenografted tumors in nude mice, drug efflux analysis, and drug efflux inhibitory assays were performed.
  • In each cell clone of NR-PG/VCR and HSY/VCR, MRP7 mRNA was induced by VCR treatment, suggesting an acquired resistance to VCR in the context of MRP7 expression.
  • Furthermore, doxorubicin accumulation was increased and drug cross-resistance to docetaxel decreased in HSY/VCR in the presence of a competitive MRP7 inhibitor, 17-beta-estradiol-(17-beta-D-glucuronide).
  • These results indicate that MDR1 expression, MRP1 expression, and MRP7 expression are refractory factors in head and neck cancer chemotherapy and suggest that induction of MRP7 expression is involved in drug resistance to natural products, especially to docetaxel in SGA.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / pharmacology. Drug Resistance, Multiple. Gene Expression Regulation, Neoplastic. Multidrug Resistance-Associated Proteins / biosynthesis. Salivary Gland Neoplasms / drug therapy. Taxoids / pharmacology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203221.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ABCC10 protein, human; 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / RNA, Messenger; 0 / Taxoids; 15H5577CQD / docetaxel; 1806-98-0 / estradiol-17 beta-glucuronide; 4TI98Z838E / Estradiol
  •  go-up   go-down


9. Asaumi J, Higuchi Y, Matsuzaki H, Murakami J, Kawasaki S, Kuroda M, Shibuya K, Konouchi H, Hisatomi M, Wakasa T, Kishi K, Hiraki Y: Thermochemotherapy of a human salivary adenocarcinoma cell line. Oncol Rep; 2002 Mar-Apr;9(2):365-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thermochemotherapy of a human salivary adenocarcinoma cell line.
  • We report on thermochemotherapy in a human salivary gland adenocarcinoma cell line.
  • Hyperthermia reduced the survival rate to 50 and 20% by heating at 43 degrees C for 40 and 60 min, respectively, and is by itself useful in human salivary gland carcinoma treatment.
  • Thermochemotherapy is a useful tool in the treatment of human salivary gland carcinoma cells, but it is necessary to select the best anticancer drugs and the optimal temperature for optimal success using this treatment.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / therapeutic use. Hyperthermia, Induced. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Bleomycin / therapeutic use. Cell Survival / drug effects. Cisplatin / therapeutic use. Combined Modality Therapy. Doxorubicin / therapeutic use. Fluorouracil / therapeutic use. Humans. Mitomycin / therapeutic use. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11836609.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Agulnik M, Siu LL: An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents. Curr Med Chem Anticancer Agents; 2004 Nov;4(6):543-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents.
  • Salivary gland cancers are a rare malignancy accounting for less than 1% of all cancers and 3-6% of cancers of the head and neck region.
  • The classification of salivary gland tumors is traditionally based on morphology and the different subtypes exhibit various clinical behaviors.
  • The low grade and biologically indolent cell types include the adenoid cystic, acinic cell and adenocarcinoma while the salivary duct, squamous and mucoepidermoid are more active and high grade.
  • The initial management of salivary gland malignancies is to assess resectability and possible adjuvant radiation therapy.
  • Those with locoregional recurrence or metastatic disease are treated with systemic therapy.
  • Both single agent and combination chemotherapy have been used for the treatment of this disease.
  • Clinicopathological data have demonstrated correlations between poor clinical outcomes and the expression of molecular markers such as mutated p53 protein and vascular endothelial growth factor (VEGF) in salivary gland cancers.
  • Recent studies have also evaluated the epidermal growth factor receptor family including erbB1/EGFR and erbB2/HER2 as potential therapeutic targets.
  • Given the suboptimal response rates, duration of response, and toxicity of conventional chemotherapy, a better understanding of the biology of salivary gland malignancies will lead to improved prognostication and treatment.
  • With the emergence of molecular targeted therapy, these tumors become an optimal candidate for trials of investigational drugs and established drugs for new indications.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Delivery Systems / methods. Salivary Gland Neoplasms / drug therapy


11. Airoldi M, Fornari G, Pedani F, Marchionatti S, Gabriele P, Succo G, Bumma C: Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res; 2000 Sep-Oct;20(5C):3781-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and carboplatin for recurrent salivary gland malignancies.
  • BACKGROUND: The use of chemotherapy for recurrent salivary gland carcinomas is under investigation.
  • PATIENTS AND METHODS: Fourteen patients (10 males, 4 females; median age 55 years, range 20-70) with recurrent carcinomas of major (9 patients) and minor (5 patients) salivary gland origin (histology: 1 adenocarcinoma, 10 adenoid cystic carcinoma, 2 undifferentiated carcinoma, 1 mucoepidermoid carcinoma) were treated with carboplatin AUC 5.5 + paclitaxel 175 mg/m2 (3-hour infusion) on day 1 (interval = 3 weeks).
  • The median survival time was 13.5 months for PR/NC patients, 6 months for non responders; median overall survival was 12.5 months (3-17+).
  • CONCLUSION: This combination had a moderate activity; the treatment was well tolerated and toxicity was manageable.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Paclitaxel / administration & dosage. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11268454.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Chandana SR, Conley BA: Salivary gland cancers: current treatments, molecular characteristics and new therapies. Expert Rev Anticancer Ther; 2008 Apr;8(4):645-52
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland cancers: current treatments, molecular characteristics and new therapies.
  • Salivary gland cancers are relatively rare and quite diverse.
  • Current therapy relies on local ablation.
  • There are few large clinical trials or randomized trials to guide treatment, especially for metastatic disease.
  • This article reviews the epidemiology, staging, molecular characteristics, and treatment evidence for the most common types of salivary cancers and suggests potential future diagnostic and treatment directions.
  • Progress in understanding the molecular and cell biology of salivary gland cancers may lead to the development of targeted therapies in these rare tumors.
  • Multidisciplinary and multi-institutional collaborative studies are needed to help improve survival in salivary gland cancers.
  • [MeSH-major] Adenocarcinoma. Salivary Gland Neoplasms
  • [MeSH-minor] Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / radiography. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / drug therapy. Carcinoma, Mucoepidermoid / genetics. Carcinoma, Mucoepidermoid / radiography. Carcinoma, Mucoepidermoid / surgery. Humans. Mutation. Prognosis. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402531.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 81
  •  go-up   go-down


13. Laurie SA, Licitra L: Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol; 2006 Jun 10;24(17):2673-8
Hazardous Substances Data Bank. Trastuzumab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy in the palliative management of advanced salivary gland cancers.
  • Cancers of the salivary glands are unusual lesions that vary widely in their histologic appearance and molecular characteristics.
  • There are few data on the role of systemic therapies in the management of these cancers, and chemotherapy is generally reserved for the palliative management of advanced disease that is not amenable to local therapies such as surgery and/or radiation.
  • The majority of patients for whom systemic therapy is considered will have either adenoid cystic carcinoma, mucoepidermoid carcinoma, or high-grade adenocarcinoma.
  • This article will review the available literature regarding the use of palliative chemotherapy for patients with advanced salivary gland cancer of these histologies, with an emphasis on the potential role of targeted agents.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Mucoepidermoid / drug therapy. Neoplasm Recurrence, Local / drug therapy. Palliative Care. Salivary Ducts. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Boronic Acids / therapeutic use. Bortezomib. Clinical Trials as Topic. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Humans. Neoplasm Metastasis. Pyrazines / therapeutic use. Quinazolines / therapeutic use. Receptor, ErbB-2 / metabolism. Receptors, Androgen / metabolism. Trastuzumab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16763282.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 0 / Quinazolines; 0 / Receptors, Androgen; 0VUA21238F / lapatinib; 0W860991D6 / Deoxycytidine; 69G8BD63PP / Bortezomib; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  • [Number-of-references] 87
  •  go-up   go-down


14. Maiuri F, Gangemi M, Giamundo A, Mariniello G, Colella A, Vergara P, Del Basso De Caro ML: Intracranial extension of salivary gland tumors. Clin Neuropathol; 2010 Jan-Feb;29(1):9-13
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial extension of salivary gland tumors.
  • OBJECTIVE: The aim of this report is to describe 3 cases of salivary gland tumors with intracranial extension associated to an extracerebral mass lesion, and to discuss the frequence, pathology and treatment of these very rare localizations.
  • The primary tumors were an adenocarcinoma and a malignant oncocytoma of the parotid gland and an adenoid cystic carcinoma of the submandibular gland.
  • Surgical treatment consisted in the seemingly complete removal of 2 tumors with middle fossa localization and partial removal of the cerebellopontine angle lesion.
  • Radiotherapy was administered in all 3 cases and chemotherapy in 2.
  • CONCLUSIONS: The intracranial extension of salivary gland tumors is a very rare event.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Brain Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Brain / pathology. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040327.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Maruya S, Namba A, Matsubara A, Kakehata S, Takeda I, Shirasaki T, Hatayama Y, Nagahata M, Yokoyama J, Shinkawa H: Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel. Int J Clin Oncol; 2006 Oct;11(5):403-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel.
  • Malignant neoplasms of the salivary gland are uncommon entities in which surgical resection of the primary lesion has been accepted as a standard therapeutic option.
  • The efficacy of radiation and systemic chemotherapy has been limited for patients with recurrent, metastatic, or unresectable disease because of unfavorable response rates and the short duration of the response.
  • We treated one patient with recurrent adenoid cystic carcinoma arising from the sublingual gland and one patient with primary adenocarcinoma arising from the parotid gland with transfemoral intraarterial chemotherapy, based on full-dose cisplatin and docetaxel and concurrent external-beam radiotherapy.
  • The concomitant chemoradiotherapy of cisplatin and docetaxel seemed to be a practicable option for patients with recurrent and unresectable salivary gland carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Parotid Neoplasms / drug therapy. Parotid Neoplasms / radiotherapy. Sublingual Gland Neoplasms / drug therapy. Sublingual Gland Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Aged. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / radiotherapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Radiotherapy, Adjuvant. Taxoids / administration & dosage. Treatment Outcome

  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Jan 22;355(9200):281-3 [10675076.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561-5 [6103535.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1874-7 [1913539.001]
  • [Cites] Head Neck. 2000 Oct;22(7):687-93 [11002324.001]
  • [Cites] Arch Otolaryngol. 1982 Apr;108(4):221-4 [6280657.001]
  • [Cites] Cancer Sci. 2004 Aug;95(8):679-84 [15298732.001]
  • [Cites] Head Neck Surg. 1986 Nov-Dec;9(2):82-92 [3623942.001]
  • [Cites] Head Neck. 2002 Apr;24(4):406-10 [11933184.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4135-40 [15736464.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):541-7 [11169936.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):951-5 [3585449.001]
  • [Cites] Head Neck. 2004 Aug;26(8):681-92; discussion 692-3 [15287035.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3781-3 [11268454.001]
  • [Cites] Head Neck. 2005 Jan;27(1):65-71 [15459915.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1842-50 [8620502.001]
  • (PMID = 17058139.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Ruzich JC, Ciesla MC, Clark JI: Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report. Head Neck; 2002 Apr;24(4):406-10
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report.
  • BACKGROUND: Malignant tumors of the salivary gland are rare entities that are treated primarily by surgical resection.
  • For patients with recurrent or unresectable disease, options include radiation therapy or chemotherapy; however, responses are few and of short duration.
  • Patients with metastatic disease have been treated with chemotherapy, but, again, response rates have been low and of short duration.
  • A biopsy revealed adenocarcinoma of a minor salivary gland.
  • Ten months after surgical resection, neck dissection, and radiation therapy, the patient was found to have metastatic disease to the lung.
  • Chemotherapy was initiated with carboplatin and paclitaxel.
  • CONCLUSIONS: The use of carboplatin and paclitaxel in the setting of metastatic salivary gland cancer is a viable option.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Paclitaxel / therapeutic use. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc.
  • (PMID = 11933184.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


17. Stennert E, Kisner D, Jungehuelsing M, Guntinas-Lichius O, Schröder U, Eckel HE, Klussmann JP: High incidence of lymph node metastasis in major salivary gland cancer. Arch Otolaryngol Head Neck Surg; 2003 Jul;129(7):720-3
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of lymph node metastasis in major salivary gland cancer.
  • OBJECTIVE: To analyze the incidence and risk factors for clinically apparent and occult lymph node metastases in patients with major salivary gland cancers.
  • Patients were treated with surgery alone (55%); surgery and radiation therapy (43%); or a combination of surgery, radiation, and chemotherapy (2%).
  • Histologic diagnosis was significantly related to the incidence of lymph node metastasis: 89% (16/18) for undifferentiated carcinomas.
  • CONCLUSIONS: We found a high incidence of lymph node metastasis from major salivary gland cancers.
  • Neck dissections should be considered as an integral part of the surgical approach in patients with major salivary gland cancer, especially if no postoperative radiation therapy is planned.
  • [MeSH-major] Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Child. Disease-Free Survival. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12874071.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Zeng Q, Tang PZ, Xu ZG, Qi YF, Wu XX, Liu WS: [Malignant minor salivary gland tumors of the larynx]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Jan;44(1):40-3
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant minor salivary gland tumors of the larynx].
  • OBJECTIVE: To study the clinical features, treatment and prognosis of malignant minor salivary gland tumors of the larynx.
  • METHODS: Treatment and outcome were retrospectively analyzed in a consecutive series of 15 patients with malignant minor salivary gland tumors of the larynx treated in this hospital from 1959 to 2005.
  • Ten patients (66.7%) had adenoid cystic carcinoma and 2 (13.3%) had adenocarcinoma.
  • The other three patients had mucoepidermoid carcinomas, polymorphic adenocarcinoma and base cell carcinoma respectively.
  • Fourteen had surgery (7 with adjuvant radiotherapy) and one was treated with radiotherapy plus chemotherapy.
  • The other 4 patients were lost to follow-up after treatment (ranging from 2 years to 16 years).
  • Seven patients developed recurrent disease, 1 of whom had local recurrence alone, 1 had regional recurrence alone, 2 had distant metastases alone, and 3 had local and distant metastases.
  • CONCLUSIONS: Minor salivary gland carcinomas of the larynx are rare and they are prone to the local recurrence and the distant metastasis in advanced stage.
  • Distant metastases remain the principal cause of treatment failure.
  • Surgery is the primary treatment modality used in most cases and the radiotherapy combining surgery has better local and regional control rate.
  • [MeSH-major] Laryngeal Neoplasms / therapy. Salivary Gland Neoplasms / therapy. Salivary Glands, Minor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19484987.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Airoldi M, Pedani F, Succo G, Gabriele AM, Ragona R, Marchionatti S, Bumma C: Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer; 2001 Feb 1;91(3):541-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies.
  • BACKGROUND: Some previous studies have shown that vinorelbine (VNB) is active in recurrent salivary gland tumors.
  • Four patients had been treated with prior surgery (S) or radiotherapy (RT), 27 patients had been treated with S plus RT, and 5 patients had been treated with S plus RT plus mitoxantrone.
  • Eighteen patients had major salivary gland tumors, and 18 patients had minor salivary gland tumors; 9 patients had adenocarcinoma, 22 patients had adenoid cystic carcinoma, 1 patient had a malignant mixed carcinoma, 3 patients had undifferentiated carcinoma, and 1 patient had a mucoepidermoid carcinoma.
  • Grade 2-3 nausea and emesis was statistically higher (P < 0.001) in Arm A; there was no significant difference with regard to other side-effects between the two treatment arms.
  • CONCLUSIONS: VNB is a drug with moderate activity in salivary gland malignancies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Salivary Gland Neoplasms / drug therapy. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11169936.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


20. Shimizu A, Yamane M, Ito H, Araki S, Yoshida T, Suzuki M: [Clinicopathological study of salivary duct carcinoma]. Nihon Jibiinkoka Gakkai Kaiho; 2002 Jun;105(6):727-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological study of salivary duct carcinoma].
  • Salivary duct carcinoma (SDC) was first described by Kleinsesser in 1968 and was classified as an independent entity by the 1991 Revised World Health Organization.
  • We reviewed pathology in 49 cases of salivary adenocarcinoma, and diagnosed 6 cases as SDC.
  • All had a rapidly enlarged mass in the parotid gland.
  • Two had chemotherapy, but showed no effect.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Male. Middle Aged. Prognathism. Proliferating Cell Nuclear Antigen / analysis. Salivary Ducts / pathology. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12138700.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


21. Gilbert J, Li Y, Pinto HA, Jennings T, Kies MS, Silverman P, Forastiere AA: Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck; 2006 Mar;28(3):197-204
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group.
  • BACKGROUND: Malignant tumors of the salivary glands make up approximately 5% of head and neck cancers.
  • The Eastern Cooperative Oncology Group (ECOG) initiated a phase II evaluation of paclitaxel in patients with locally recurrent or metastatic salivary gland malignancies.
  • METHODS: Chemo-naive patients with histologically confirmed recurrent or metastatic carcinoma of salivary gland origin (mucoepidermoid, adenocarcinoma, or adenoid cystic) were eligible.
  • Eight partial responses were seen among the 31 patients with mucoepidermoid or adenocarcinoma histologic findings for a response rate of 26%.
  • CONCLUSION: Paclitaxel demonstrates moderate activity in salivary gland tumors of mucoepidermoid and adenocarcinoma histology.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / therapeutic use. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Mucoepidermoid / drug therapy. Carcinoma, Mucoepidermoid / mortality. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 16470745.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA14548; United States / NCI NIH HHS / CA / CA16116; United States / NCI NIH HHS / CA / CA17145; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


22. Pogodzinski MS, Sabri AN, Lewis JE, Olsen KD: Retrospective study and review of polymorphous low-grade adenocarcinoma. Laryngoscope; 2006 Dec;116(12):2145-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective study and review of polymorphous low-grade adenocarcinoma.
  • OBJECTIVES/HYPOTHESIS: We review a single institution's experience with polymorphous low-grade adenocarcinoma.
  • To our knowledge, this is the largest patient series of polymorphous low-grade adenocarcinoma with clinical follow-up in the otolaryngology literature.
  • STUDY DESIGN: We retrospectively identified 19 patients with polymorphous low-grade adenocarcinoma who had adequate clinical follow-up and pathologic specimens available for examination.
  • Fifteen patients had their initial treatment at our institution, and four patients presented with a recurrent tumor.
  • One patient had regional nodal disease 20 years after the initial procedure, and another had lung metastasis.
  • No patients received chemotherapy.
  • The most common initial diagnoses were polymorphous low-grade adenocarcinoma, adenoid cystic carcinoma, and pleomorphic adenoma.
  • CONCLUSIONS: Polymorphous low-grade adenocarcinoma is an increasingly recognized malignancy that originates predominantly in the minor salivary gland.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Salivary Glands, Minor


23. Okamoto M, Ohe G, Furuichi S, Nishikawa H, Oshikawa T, Tano T, Ahmed SU, Yoshida H, Moriya Y, Matsubara S, Ryoma Y, Saito M, Sato M: Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells. Anticancer Res; 2002 Nov-Dec;22(6A):3229-39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells.
  • BACKGROUND: OK-PSA, a lipoteichoic acid (LTA)-related molecule isolated from a streptococcal agent OK-432, enhances anti-tumor immunity as a potent inducer of Th1-type cytokines.
  • MATERIALS AND METHODS: We conducted the animal experiments using athymic nude mice bearing human salivary adenocarcinoma to examine the role of NK cells in OK-PSA-induced anti-tumor immunity.
  • RESULTS: OK-PSA markedly increased the amounts of IFN-gamma, tumor necrosis factor (TNF)-alpha, interleukin (IL)-2, IL-12 and IL-18 that are generally called "Th1-type cytokines" in the sera derived from tumor-bearing nude mice, and also accelerated the killing activities of tumor-infiltrating lymphocytes as well as of draining lymph node cells.
  • [MeSH-major] Adenocarcinoma / immunology. Adenocarcinoma / therapy. Killer Cells, Natural / immunology. Lipopolysaccharides / pharmacology. Salivary Gland Neoplasms / immunology. Salivary Gland Neoplasms / therapy. Teichoic Acids / pharmacology
  • [MeSH-minor] Animals. Antibodies / immunology. Antibodies / pharmacology. Cell Movement / drug effects. Cell Movement / immunology. Cell Movement / radiation effects. Combined Modality Therapy. Cytokines / biosynthesis. Cytokines / blood. Cytokines / genetics. G(M1) Ganglioside / immunology. Humans. Immunotherapy / methods. Lymphocytes / drug effects. Lymphocytes / immunology. Lymphocytes / radiation effects. Lymphocytes, Tumor-Infiltrating / immunology. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Nitric Oxide / biosynthesis. Nitric Oxide Synthase / biosynthesis. Nitric Oxide Synthase Type II. Picibanil / chemistry. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Th1 Cells / immunology. Th1 Cells / metabolism. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12530069.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies; 0 / Cytokines; 0 / Lipopolysaccharides; 0 / RNA, Messenger; 0 / Teichoic Acids; 31C4KY9ESH / Nitric Oxide; 37758-47-7 / G(M1) Ganglioside; 39325-01-4 / Picibanil; 56411-57-5 / lipoteichoic acid; 71012-19-6 / asialo GM1 ganglioside; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nos2 protein, mouse
  •  go-up   go-down


24. Manor E, Sion-Vardy N, Bodner L: Cytogenetic and fluorescence in situ hybridization analysis of a basal cell adenocarcinoma of the mandible. Cancer Genet Cytogenet; 2006 Apr 15;166(2):186-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic and fluorescence in situ hybridization analysis of a basal cell adenocarcinoma of the mandible.
  • Basal cell adenocarcinoma (BCAC) of the salivary glands is rare.
  • Distant metastasis to the mandible from a salivary gland tumor is also considered rare.
  • An 80-year-old female with primary BCAC of the parotid salivary gland underwent parotidectomy and chemotherapy.
  • Tissue specimens from the mandibular lesion were tested by the following pathologic methods: hematoxylin-eosin and immunohistochemistry for CK8/18, CK/903, vimentin, and smooth muscle actin.
  • The characteristic histologic architecture of BCAC found in the mandible was similar to that of the earlier findings of the tumor in the parotid gland.
  • [MeSH-major] Adenocarcinoma / genetics. Mandibular Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631478.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Numata T, Hiruma K, Tsukuda T, Asano T: [Malignant mixed tumor]. Gan To Kagaku Ryoho; 2004 Mar;31(3):314-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to the data of the Japanese committee on TNM classification for salivary gland carcinomas, carcinoma in pleomorphic adenoma accounted for about 10% of all salivary gland carcinomas, both in the parotid and submandibular glands.
  • The main type of carcinomas arising in pleomorphic adenoma were undifferentiated carcinoma, adenocarcinoma and squamous cell carcinoma.
  • The treatment of choice for carcinoma in pleomorphic adenoma has consisted of en-bloc excision with wide margin.
  • Invasive growth, facial nerve involvement, lymph node metastasis or high-grade malignant tumor are grounds for postoperative radiation therapy.
  • The role of chemotherapy has not yet been well established.
  • [MeSH-major] Mixed Tumor, Malignant. Salivary Gland Neoplasms
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Carcinosarcoma / diagnosis. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15045931.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Berger AK, Bellos F, Siegmund A, Eisenbach C, Lordick F: Symptomatic hyponatraemia caused by cylophosphamide. Onkologie; 2009 May;32(5):280-2
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: A 69-year-old female patient with metastatic adenocarcinoma of the salivary glands presented with severe symptomatic hyponatraemia (nadir 112 mmol/l) after chemotherapy with cyclophosphamide, cisplatin, and doxorubicin.
  • CONCLUSION: Oncologists should be aware of cyclophosphamide-induced acute hyponatraemia as a rare but life-threatening side-effect, especially since its clinical features may mimic those of chemotherapy-induced nausea.
  • [MeSH-major] Cyclophosphamide / adverse effects. Hyponatremia / chemically induced. Hyponatremia / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 S. Karger AG, Basel.
  • (PMID = 19420976.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


27. Bianciotto C, Demirci H, Shields CL, Eagle RC Jr, Shields JA: Metastatic tumors to the eyelid: report of 20 cases and review of the literature. Arch Ophthalmol; 2009 Aug;127(8):999-1005
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the primary sites, clinical features, treatment, and outcome of 20 patients with cancer metastatic to the eyelids.
  • RESULTS: The primary tumors included skin melanoma (4 [20%]), uveal melanoma (4 [20%]), breast carcinoma and conjunctival melanoma (3 [15%] each), renal cell carcinoma (2 [10%]), and medullary thyroid carcinoma, prostate carcinoma, lung carcinoma, and salivary gland carcinoma (1 [5%] each).
  • Primary treatment included excision alone in 6 patients (30%), external beam radiotherapy in 7 (35%), systemic chemotherapy in 4 (20%), and observation in 3 (15%).
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Renal Cell / secondary. Eyelid Neoplasms / secondary. Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Middle Aged. Ophthalmologic Surgical Procedures. Radiotherapy. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667336.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 19
  •  go-up   go-down


28. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB: Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck; 2002 Sep;24(9):821-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the role of radiation therapy in patients with nasal cavity and paranasal sinus tumors.
  • MATERIALS AND METHODS: Between October 1964 and July 1998, 78 patients with malignant tumors of the nasal cavity (48 patients), ethmoid sinus (24 patients), sphenoid sinus (5 patients), or frontal sinus (1 patient) were treated with curative intent by radiation therapy alone or in the adjuvant setting.
  • There were 25 squamous cell carcinomas, 14 undifferentiated carcinomas, 31 minor salivary gland tumors (adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma), 8 esthesioneuroblastomas, and 1 transitional cell carcinoma.
  • Forty-seven patients were treated with irradiation alone, 25 with surgery and postoperative irradiation, 2 with preoperative irradiation and surgery, and 4 with chemotherapy in combination with irradiation with or without surgery.
  • Of the 67 (86%) patients who were initially seen with node-negative disease, 39 (58%) received no elective neck treatment, and 28 (42%) received elective neck irradiation.
  • Of the 39 patients who received no elective neck treatment, 33 (85%) did not experience recurrence in the neck compared with 25 (89%) of 28 patients who received elective neck irradiation.
  • CONCLUSION: Surgery and postoperative radiation therapy may result in improved local control, absolute survival, and complications when compared with radiation therapy alone.
  • [MeSH-major] Carcinoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blindness / etiology. Blindness / prevention & control. Cause of Death. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Osteoradionecrosis / etiology. Postoperative Care. Preoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 821-829, 2002
  • (PMID = 12211046.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Okamoto M, Gohda H, Ohe G, Yoshida H, Matsuno T, Saito M, Sato M: Cytokine-inducing activity and antitumor effect of a liposome-incorporated interferon-gamma-inducing molecule derived from OK-432, a streptococcal preparation. J Immunother; 2000 Jan;23(1):94-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the current study, the liposomes were used to improve the delivery of the agent (OK-PSA) to effector cells and to increase the therapeutic effect.
  • In in vivo experiments, Lipo-OK-PSA elicited striking anti-tumor activity on syngeneic Meth-A tumor-bearing and colon 26-bearing BALB/c mice and on salivary gland tumor-bearing nude mice far better than did OK-PSA.
  • [MeSH-minor] Adenocarcinoma. Animals. Cells, Cultured. Cytokines. Cytotoxicity, Immunologic. Drug Carriers. G(M1) Ganglioside / immunology. Humans. Killer Cells, Lymphokine-Activated / immunology. Killer Cells, Natural / immunology. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / immunology. Liposomes. Mice. Mice, Inbred BALB C. Salivary Gland Neoplasms. Sarcoma, Experimental / drug therapy. Sarcoma, Experimental / physiopathology. Spleen / cytology. Spleen / immunology. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10687142.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Drug Carriers; 0 / Interleukin-1; 0 / Liposomes; 0 / Lymphotoxin-alpha; 0 / Tumor Necrosis Factor-alpha; 37758-47-7 / G(M1) Ganglioside; 39325-01-4 / Picibanil; 71012-19-6 / asialo GM1 ganglioside; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


30. Tijink BM, De Bree R, Van Dongen GA, Leemans CR: How we do it: Chemo-electroporation in the head and neck for otherwise untreatable patients. Clin Otolaryngol; 2006 Oct;31(5):447-51
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Keypoints * Chemo-electroporation therapy with bleomycin is a locoregional treatment modality for head and neck and skin cancer, with the potential to preserve function.
  • * In our institution, chemo-electroporation therapy is used for patients that can no longer be treated by surgery or radiotherapy, or for whom surgical treatment would be very extensive and thus declined by the patient.
  • * This paper describes in detail the technique of bleomycin-electroporation therapy.
  • * The main focus of the trial is to determine the safety, effectiveness, and burden of bleomycin-electroporation therapy for the patient.
  • * All 17 tumours responded to therapy.
  • * Based on the outcome of the clinical trial, bleomycin-electroporation therapy has the potential to become a valuable addition to the late-stage treatment options for patients with head and neck or skin tumours.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Electroporation / methods. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / secondary. Carcinoma, Basal Cell / therapy. Carcinoma, Merkel Cell / secondary. Carcinoma, Merkel Cell / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Melanoma / secondary. Melanoma / therapy. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Netherlands. Salivary Gland Neoplasms / secondary. Salivary Gland Neoplasms / therapy. Sarcoma / secondary. Sarcoma / therapy. Skin Neoplasms / secondary. Skin Neoplasms / therapy. Treatment Outcome. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17014460.001).
  • [ISSN] 1749-4478
  • [Journal-full-title] Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  • [ISO-abbreviation] Clin Otolaryngol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


31. White JD, Junor EJ, McGarva J, McManners J, Holland IS: Adenocarcinoma of the salivary gland? A chemo-sensitive disease. Clin Oncol (R Coll Radiol); 2004 Apr;16(2):159-60
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the salivary gland? A chemo-sensitive disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leeching. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Epirubicin / administration & dosage. Fluorouracil / administration & dosage. Humans. Lymphedema / etiology. Lymphedema / therapy. Male. Middle Aged. Palliative Care. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15074745.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; FPEPIR regimen
  •  go-up   go-down






Advertisement